Jubilant Pharmova (BSE:530019) - Share price, News & Analysis

530019 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	2/6
Financial Health	5/6
Dividends	5/6

530019 Stock Overview

Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide.

Rewards

Trading at 18.4% below our estimate of its fair value

Earnings are forecast to grow 20.42% per year

Pays a reliable dividend of 1.21%

Risk Analysis

Has a high level of debt

Jubilant Pharmova Competitors

Cipla

NSEI:CIPLA

₹772.2b

Aurobindo Pharma

NSEI:AUROPHARMA

₹327.9b

Laurus Labs

BSE:540222

₹304.5b

Hikal

BSE:524735

₹48.7b

Price History & Performance

Summary of all time highs, changes and price drops for Jubilant Pharmova
Historical stock prices
Current Share Price	₹412.50
52 Week High	₹925.00
52 Week Low	₹384.85
Beta	2.15
1 Month Change	-10.59%
3 Month Change	-6.07%
1 Year Change	-50.54%
3 Year Change	-20.65%
5 Year Change	-42.95%
Change since IPO	1,746.16%

Shareholder Returns

	530019	IN Pharmaceuticals	IN Market
7D	2.4%	3.1%	1.7%
1Y	-50.5%	-10.9%	10.5%

Return vs Industry: 530019 underperformed the Indian Pharmaceuticals industry which returned -10.4% over the past year.

Return vs Market: 530019 underperformed the Indian Market which returned 10.6% over the past year.

Price Volatility

Is 530019's price volatile compared to industry and market?
530019 volatility
530019 Average Weekly Movement	6.6%
Pharmaceuticals Industry Average Movement	7.0%
Market Average Movement	7.3%
10% most volatile stocks in IN Market	10.0%
10% least volatile stocks in IN Market	4.8%

Stable Share Price: 530019 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 530019's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1978	6,000	Hari Shanker Bhartia	https://www.jubilantpharmova.com

Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States.

Jubilant Pharmova Fundamentals Summary

How do Jubilant Pharmova's earnings and revenue compare to its market cap?
530019 fundamental statistics
Market Cap	₹65.67b
Earnings (TTM)	₹5.27b
Revenue (TTM)	₹61.82b

12.5x

P/E Ratio

1.1x

P/S Ratio

Is 530019 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
530019 income statement (TTM)
Revenue	₹61.82b
Cost of Revenue	₹14.62b
Gross Profit	₹47.20b
Other Expenses	₹41.93b
Earnings	₹5.27b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

May 20, 2022

Earnings per share (EPS)	33.12
Gross Margin	76.35%
Net Profit Margin	8.53%
Debt/Equity Ratio	57.8%

How did 530019 perform over the long term?

See historical performance and comparison

Dividends

1.2%

Current Dividend Yield

15%

Payout Ratio

Valuation

Is Jubilant Pharmova undervalued compared to its fair value and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

18.4%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: 530019 (₹412.5) is trading below our estimate of fair value (₹505.81)

Significantly Below Fair Value: 530019 is trading below fair value, but not by a significant amount.

Price To Earnings Ratio

PE vs Industry: 530019 is good value based on its PE Ratio (12.5x) compared to the Indian Pharmaceuticals industry average (21.4x).

PE vs Market: 530019 is good value based on its PE Ratio (12.5x) compared to the Indian market (20.6x).

Price to Earnings Growth Ratio

PEG Ratio: 530019 is good value based on its PEG Ratio (0.6x)

Price to Book Ratio

PB vs Industry: 530019 is good value based on its PB Ratio (1.3x) compared to the IN Pharmaceuticals industry average (2.6x).

Future Growth

How is Jubilant Pharmova forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

20.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 530019's forecast earnings growth (20.4% per year) is above the savings rate (6.7%).

Earnings vs Market: 530019's earnings (20.4% per year) are forecast to grow faster than the Indian market (18.6% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 530019's revenue (7.8% per year) is forecast to grow slower than the Indian market (11.9% per year).

High Growth Revenue: 530019's revenue (7.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 530019's Return on Equity is forecast to be low in 3 years time (10.9%).

Past Performance

How has Jubilant Pharmova performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

3.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 530019 has high quality earnings.

Growing Profit Margin: 530019's current net profit margins (8.5%) are lower than last year (9%).

Past Earnings Growth Analysis

Earnings Trend: 530019's earnings have grown by 3.4% per year over the past 5 years.

Accelerating Growth: 530019's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 530019 had negative earnings growth (-36.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.5%).

Return on Equity

High ROE: 530019's Return on Equity (10.3%) is considered low.

Financial Health

How is Jubilant Pharmova's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: 530019's short term assets (₹32.6B) exceed its short term liabilities (₹11.6B).

Long Term Liabilities: 530019's short term assets (₹32.6B) exceed its long term liabilities (₹32.1B).

Debt to Equity History and Analysis

Debt Level: 530019's net debt to equity ratio (40.9%) is considered high.

Reducing Debt: 530019's debt to equity ratio has reduced from 112.3% to 57.8% over the past 5 years.

Debt Coverage: 530019's debt is well covered by operating cash flow (54.3%).

Interest Coverage: 530019's interest payments on its debt are well covered by EBIT (7.8x coverage).

Balance Sheet

Dividend

What is Jubilant Pharmova current dividend yield, its reliability and sustainability?

Dividend Score

5/6

Dividend Score 5/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

1.21%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 530019's dividend (1.21%) is higher than the bottom 25% of dividend payers in the Indian market (0.35%).

High Dividend: 530019's dividend (1.21%) is low compared to the top 25% of dividend payers in the Indian market (1.58%).

Stability and Growth of Payments

Stable Dividend: 530019's dividends per share have been stable in the past 10 years.

Growing Dividend: 530019's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (15.1%), 530019's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (7.8%), 530019's dividend payments are thoroughly covered by cash flows.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

7.9yrs

Average management tenure

CEO

Hari Shanker Bhartia (65 yo)

40.33yrs

Tenure

₹121,803,665

Compensation

Mr. Hari Shanker Bhartia, B.E., B.Tech, serves as Non-Executive Director at DP Eurasia N.V. since April 21, 2021. He serves as the Non-Executive Independent Director of Shriram Pistons & Rings Limited sinc...

CEO Compensation Analysis

Compensation vs Market: Hari Shanker's total compensation ($USD1.57M) is above average for companies of similar size in the Indian market ($USD338.05K).

Compensation vs Earnings: Hari Shanker's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: 530019's management team is seasoned and experienced (7.9 years average tenure).

Board Members

Experienced Board: 530019's board of directors are considered experienced (5 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/18 00:00
End of Day Share Price	2022/05/18 00:00
Earnings	2021/12/31
Annual Earnings	2021/03/31